DUBLIN, IRELAND, OXFORD, UK, and PHILADELPHIA, PA -- August 5th, 2025 – SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today...
Gilde Healthcare company Shoulder Innovations Announces Pricing of Initial Public Offering
Shoulder Innovations, Inc. (“Shoulder Innovations”), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the pricing of its initial public offering of 5,000,000...
31 July 2025
Gilde Healthcare’s Private Equity-Fonds kombiniert Artinis und NIRx zu einer weltweit führenden Neuroimaging-Gruppe
Gilde Healthcare gibt heute eine kombinierte Private-Equity-Investition in Artinis Medical Systems (Niederlande) und NIRx Medical Technologies (Deutschland/Vereinigte Staaten) bekannt. Beide Unternehmen sind Pioniere auf dem Gebiet der funktionellen Nahinfrarot-Spektroskopie (fNIRS)....
8 July 2025
Gilde Healthcare company SynOx Therapeutics Completes Enrollment in Registrational Trial Significantly Ahead of Timeline
DUBLIN, IRELAND, OXFORD, UK, and PHILADELPHIA, PA -- August 5th, 2025 – SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today...
5 August 2025
Filter & Suche
Fondsstrategie :
Loading...
Das waren alles Artikel
3f126b7d75